Kuros Biosciences Ltd. appoints Chief Medical Officer

Schlieren (Zurich), Switzerland, March 8, 2016 – Kuros Biosciences Ltd. ("Kuros" or the "Company"), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect.

Dr. Jamieson has spent over 25 years in the pharmaceutical industry and has considerable experience in early and late stage clinical development, product registration and medical affairs. Dr. Jamieson received her medical degree at Edinburgh University and obtained a postgraduate fellowship in anesthesia from the Royal College of Surgeons in London. In addition, she has a diploma from the Faculty of Pharmaceutical Medicine where she has also been an appraiser for revalidation of physicians in the pharmaceutical industry. Dr. Jamieson already worked for Kuros from 2005 to 2012 as Medical Director and then as Chief Medical Officer and is therefore very familiar with Kuros' products.

Didier Cowling, CEO of Kuros, said: "We are delighted to have Virginia join us again. Her wealth of experience, both in the surgical field and pharmaceutical and medical industry, coupled with her deep knowledge of Kuros' products, makes this a key appointment for us."


For further information, please contact:

Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: +41 44 733 46 46
[email protected]


About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products for tissue repair and regeneration and is located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN.


Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.kuros.ch

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.